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Abstract
( )Vascular endothelial growth factor VEGF plays a fun-
damental role in mediating tumor angiogenesis and
tumor growth. Here we investigate the direct effect of a
novel small molecule inhibitor of the Flk-1-mediated
signal transduction pathway of VEGF, SU5416, on tu-
mor angiogenesis and microhemodynamics of an ex-
perimental glioblastoma by using intravital multifluores-
cence videomicroscopy. SU5416 treatment significantly
suppressed tumor growth. In parallel, SU5416 demon-
strated a potent antiangiogenic activity, resulting in a
significant reduction of both the total and functional
vascular density of the tumor microvasculature, which
indicates an impaired vascularization as well as signifi-
cant perfusion failure in treated tumors. This malperfu-
sion was not compensated for by changes in vessel
diameter or recruitment of nonperfused vessels. Analy-
ses of the tumor microcirculation revealed significant
microhemodynamic changes after angiogenesis block-
age such as a higher red blood cell velocity and blood
flow in remnant tumor vessels when compared with
controls. Our results demonstrate that the novel antian-
giogenic concept of targeting the tyrosine kinase of
Flk-1/KDR by means of a small molecule inhibitor rep-
resents an efficient strategy to control growth and pro-
gression of angiogenesis-dependent tumors. This study
provides insight into microvascular consequences of
Flk-1/KDR targeting in vivo and may have important
implications for the future treatment of angio-
genesis-dependent neoplasms.
Keywords: antiangiogenic therapy, protein tyrosine kinase, glioma, vasculariza-
( )tion, vascular endothelial growth factor VEGF .
Introduction
Angiogenesis is the continuous formation of new blood
vessels from the existing vasculature. Without angiogene-
sis, most solid tumors do not progress to a clinically relevant
size due to inadequate tissue oxygenation and nutritional
[ ]supply 1 . The process of tumor angiogenesis is mediated
by angiogenic growth factors and their cognate receptors
[ ]via a paracrine mechanism 2 . Targeting of angiogenic
signal transduction pathways represents a promising alter-
native in the treatment of neoplasms that are resistant to the
therapeutic armamentarium of surgery, radiotherapy, and
cytotoxic chemotherapy. Among these are high-grade
( )gliomas glioblastoma multiforme that are the most malig-
nant brain tumors, with a mean survival time of 9 to 12
months and a high resistance to conventional oncology
therapy. Because they are among the most highly vascular-
ized human tumors they should be ideal candidates for
[ ]antiangiogenic therapy 3 .
( )Vascular endothelial growth factor VEGF , also known
( )as vascular permeability factor VPF , is an endothelial
cell-specific mitogen in vitro, as well as a potent angiogenic
growth factor and mediator of microvascular hyperperme-
[ ]ability in vivo 4,5 . This dimeric glycoprotein has a signifi-
cant sequence homology with platelet-derived growth factor
( ) [ ] ( ) [ ]PDGF 6 and placenta growth factor PlGF 7 and is
expressed in at least 4 different molecular isoforms of 206,
189, 165 and 121 amino acids as a result of alternative
splicing of mRNA. Among these, VEGF165 is the predomi-
nantly expressed isoform in most human tissues, including
[ ]the central nervous system 5 . The biological effects of
VEGF are mediated by 2 high-affinity receptors, the class III
( ) ( ) [ ]protein tyrosine kinases PTKs VEGFR-1 Flt-1 8 and
( ) [ ]VEGFR-2 Flk-1/KDR 9 , which are almost exclusively
expressed on microvascular endothelial cells. These two
receptors may serve distinct functions, including endothelial
cell proliferation and chemotaxis, monocyte migration, and
[ ]cell to cell or cell to matrix interaction 10–12 .
A substantial body of evidence has emerged suggesting
that the VEGF-Flk-1/KDR system is the dominant signal
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tranduction pathway regulating glioma-induced angiogene-
sis. First, temporal and spatial expression patterns of VEGF,
Flk-1/KDR, and Flt-1 correlate significantly with the angio-
[ ]genic activity in human gliomas 13,14 . Second, both ad-
[ ]ministration of a neutralizing anti-VEGF antibody 15 and
interference with the Flk-1/KDR-mediated signal transduc-
[ ]tion pathway by using a dominant-negative strategy 16
inhibited glioma growth in the athymic mouse. Third, Flt-1 is
not associated with endothelial cell mitogenicity and en-
dothelial cell chemotaxis, but rather with the regulation of
endothelial cell to cell and cell to matrix interactions during
[ ]vascular development 10,11 . Therefore, considerable in-
terest has been developed in selective targeting of the
VEGF-Flk-1/KDR signaling pathway for antiglioma therapy.
Small molecule inhibitors of tyrosine phosphorylation on
Flk-1/KDR, which belong to the tyrphostins, quinoxalines
and quinazolinones chemical classes, have been shown to
[ ]possess antiangiogenic activities in vitro 17 . More re-
cently, SU5416, a novel and selective inhibitor of the tyro-
[ ]sine kinase activity of Flk-1/KDR has been identified 18 .
SU5416 and related compounds have been shown to func-
tion as adenine mimetics at the catalytic domain of the
[ ]tyrosine kinase 19 . In in vitro studies, SU5416 exerts a
potent, rapid, and long-lasting antiproliferative effect on en-
dothelial cells without directly affecting growth of tumor cells
[ ]in culture 18 . In vivo, parenteral administration of SU5416
resulted in an inhibition of growth of multiple tumor types of
[ ]various tissue origins 18 .
The objective of the present study was to assess the in
vivo effect of SU5416 on tumor growth, tumor-induced an-
giogenesis, and tumor microcirculation and, thereby, to fur-
ther define the mechanism of its in vivo action as well as
the microhemodynamic consequences following Flk-1/KDR
inhibition. The use of the dorsal skinfold chamber prepara-
[ ]tion in the athymic mouse 20 represents a unique tool to
study the dynamic processes of angiogenesis and mi-
crovascular perfusion patterns of normal and neoplastic
( )tissue e.g., adenocarcinoma, high-grade glioma by direct,
[ ]continuous, and noninvasive means 21–24 . We report for
the first time that tumor growth suppression by SU5416 is
)accompanied by 1 direct inhibitory effects on microvascular
proliferation and thus a reduced total as well as functional
)vascular density, and 2 microhemodynamic changes with
an increase in blood perfusion in individual remnant tumor
vessels. These results are of considerable interest for the
further characterization of the novel therapeutic concept of
small-molecule Flk-1/KDR inhibitors and the understanding
of the microcirculatory consequences of this antiangiogenic
intervention, thus assisting in the design of future therapeu-
tic strategies for Flk-1/KDR intervention in oncology.
Materials and Methods
Cells and Cell Culture
C6 rat glioma cells were cultured in HAM’s F-10 culture
medium in 12-well dishes at 378C in humidified atmosphere
with 5% carbon dioxide in air. A suspension of 5=105 cells
was implanted into the skin chamber for tumor growth
[ ]studies as previously described in detail 24 .
Animals and Dorsal Skinfold Chamber Model
( )Athymic nude mice nu/nu; male, 28–32 g were bred
and maintained within a specific pathogen germ-free envi-
ronment. The technique for implantation of the dorsal skin-
[ ]fold chamber has been previously described 20,24 . Briefly,
animals were anesthetized by subcutaneous injections of
7.5 mg ketamine hydrochloride and 2.5 mg xylazine per 100
mg body weight. Two symmetrical titanium frames were
implanted into the dorsal skinfold of animals to sandwich the
extended double layer of skin and create the dorsal skinfold
chamber which consists of one layer of striated muscle,
subcutaneous tissue, and epidermis. An observation win-
dow, covered with a glass cover slip, allowed for repeated
intravital microscopic observations of the microvasculature
of the tumor growing in the chamber. The backside of the
chamber preparation remained open, allowing a 3-dimen-
sional quantitation of the growth of the implanted glioma.
Two days after chamber preparation, the coverslip of the
dorsal skinfold chamber was temporarily removed and a
suspension of tumor cells placed on the surface of the
striated skin muscle. The animals tolerated the skinfold
chambers well and showed no signs of discomfort or
changes in sleeping and feeding behavior.
Experimental Protocol
( )Animals ns7 were treated daily with an intraperitoneal
( ) ( )IP bolus SU5416 in DMSO 25 mg/kg in 50 mL DMSO ,
starting on the day of glioma cell implantation. The dose of
[ ]SU5416 was selected by toxicity studies 18 , identifying 25
mg/kg per day as the maximum tolerated dose that does
not cause significant toxicity in the mouse. Furthermore,
previous studies had shown that SU5416 at this dose has
no effects on macrohemodynamics or rheologic parameters
( )TAT Fong, data not shown , thus ruling out the theory that
potential microhemodynamic changes during treatment
might be related to blood pressure or hematocrit alterations.
Animals in the control groups received either the vehicle
( ) ( )DMSO ns3, 50 mL or saline ns3, 50 mL . Animals
were weighed regularly and observed for behavioral
changes. The macroscopic appearance of the skinfold
chamber preparation and the implanted glioma was docu-
mented daily. Intravital multi-fluorescence microscopic stud-
ies of glioma growth, angiogenesis, and microcirculation
were performed on days 6, 10, 14, 18, and 22 after glioma
cell implantation. During the days of observation, the newly
formed microvasculature within the fluorescently labeled
( )glioma mass intratumorally and at the glioma periphery
( )peritumorally , i.e., outside the tumor and next to the tumor
edge, was separately assessed. Measurements on vascular
density and microhemodynamics included only newly formed
tumor microvessels which can be clearly distinguished by
their chaotic arrangement from the autochthonous host stri-
ated muscle microvessels displaying the typical parallel
[ ]arrangement of the muscle capillaries 24,25 . Vascular den-
sities were measured in 6 to 9 regions of interest per animal
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and per observation time point. Microvascular diameters as
well as hemodynamic parameters were determined by
analysing 5 to 10 microvessels per region of interest. At the
(end of the in vivo experiments 22 days after glioma cell
)implantation , the animals were sacrificed with an overdose
of ketamine/xylazine, and the skinfold chamber prepara-
tions were processed for light microscopic analyses.
Intravital Multi-fluorescence Videomicroscopy
(Intravital multi-fluorescence videomicroscopy epi-il-
)lumination was performed with a modified Axiotech vario
microscope with a 100-W mercury lamp attached to a
Ploema-Pak illuminator with an ultraviolet excitation wave
) ( )length: 340–380 nm and a blue 450–490 nm filter block
( )Zeiss, Oberkochen, Germany . Observations were made
with 3.2= long distance, 10= long distance, and 20=
( )water immersion working objectives all Zeiss , resulting in
magnifications of 71= , 216= , and 435= , respectively.
The glioma cells and microvasculature were visualized by
( )means of a low-light level CCD charge-coupled device
( )video camera Cohu FK 6990, Pieper, Schwerte, Germany .
Microscopic images were recorded with a S-VHS videosys-
( )tem Panasonic, Munich, Germany for off-line analysis.
Before tumor inoculation, C6 glioma cells were fluorescently
(labeled with the fluorescent vital dye Fast Blue 10 mg/mL;
) [ ]Sigma Chemical Co, St. Louis, MO 26 for a 2-hour incu-
bation period. With ultraviolet light the dye is characterized
by a bright blue fluorescence with only little bleaching and
persists through several cell generations. Because it
demonstrates sufficient staining even after 3 weeks without
affecting cell viability, it has been widely used in studies on
[ ]glioma growth and glioma cell infiltration in vivo 26–28 .
The specific fluorescence/background fluorescence ratio
was still high enough at the end of the 22-day observation
period to detect individual tumor cells and, thus, to precisely
delineate the tumor mass from the surrounding unaffected
host tissue. With this technique of tumor cell prelabeling, the
C6 glioma exhibits a rapid tumor growth in the dorsal
skinfold chamber model to a size of approximately 60 mm2
( 3) [ ]400 mm after 22 days 24 . The vascular compartment,
including angiogenic sprouts, newly formed microvessels,
and the glioma microvasculature were visualized by con-
trast enhancement with 2% fluorescein isothiocyanate
( ) (FITC -conjugated dextran 0.1 mL FITC-dextran intra-150
)venous; mol wts150,000; Sigma under blue light epi-il-
[ ]lumination. As previously described 24 , extravasation of
FITC-dextran was analyzed 15 minutes after administra-150
tion, applying the following semiquantitative score: no ex-
( ) (travasation y ; moderate extravasation increased ex-
travasal gray levels without negatively contrasted microvas-
) ( ) ( )cular imaging forming a patchy q or homogeneous qq
pattern; extravasation with negatively contrasted microvas-
)cular imaging qqq .
Analyzed Parameters
All intravital microscopic measurements were performed
(by computer-assisted image analysis system CAPIMAGE;
)Zeintl Software Engineering, Heidelberg, Germany . Tumor
growth was assessed by measurement of the tissue area
covered by the fluorescently labeled tumor mass within the
( 2) ( 3)chamber mm , and tumor volume mm was calculated
by using the equation Vs2/3=A=h, where A is the area
of the tumor mass and h is the thickness of the tumor
bulging out at the chamber back side. The thickness of the
tumor was measured after each intravital microscopic analy-
sis with a caliper. Particular care was taken to avoid com-
pression of the tissue and its microvasculature. Quantitative
analysis of microcirculatory parameters included the angio-
( )genic take rate % , which was defined as the percentage of
( )gliomas inducing the formation of red blood cell RBC -per-
fused microvessels; the tissue area covered by the newly
( 2)formed microvascular network mm ; the total vascular
( y1)density cm , which was defined as the length of all newly
formed microvessels per area of interest and observation
( y1)time point; the functional vascular density cm , which
was defined as length of RBC-perfused microvessels per
area of interest and observation time point; microvessel
( ) ( )diameters mm , and microvascular RBC velocities mm/s .
A perfusion index PI was calculated as the percentage of
( )the functional vascular density FVD and total vascular
( )density TVD as follows: PIsFVD/TVD=100. Blood flow
( )rate Q in nanoliter/s of individual microvessels was calcu-v
( )2lated according to Q s p = D / 2 =RBCV /K, wherev
RBCV represents the RBC velocity, D represents the mi-
crovessel diameter, and K is the Baker/Wayland factor
( ) [ ]s1.3 29 considering the parabolic velocity profile of
blood in microvessels. Newly formed glioma microvessels
were not categorized into arterioles, capillaries, and venules
because this classification is based on morphological and
physiological criteria for normal tissue and might not be
[ ]applicable to tumors 30 .
Statistical Analyses
Quantitative data are given as mean values"standard
deviation. Mean values of microcirculatory data were calcu-
lated from the average values in each animal. For analysis
of differences between the groups, post-hoc unpaired Bon-
ferroni t test was used following one-way analysis of vari-
( )ance ANOVA . Results with P values of - .05 were con-
sidered significant.
Histology
Upon completion of experiments, the glioma containing
dorsal skinfold chamber preparations were excised, fixed
over 48 hours with 10% paraformaldehyde, and embedded
in paraffin. For histomorphological analyses, 5 mm sections
were prepared and stained with hematoxylin/eosin.
Results
The effect of Flk-1/KDR tyrosine kinase inhibition on glioma
growth, angiogenesis, and microcirculation was studied.
Athymic nude mice were treated daily with SU5416 begin-
ning on the day of glioma cell implantation. Control animals
( )receiving the vehicle DMSO or saline ns3 each showed
no significant difference in any of the evaluated parameters
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Figure 1. Influence of Flk-1 tyrosine kinase inhibition on C6 glioma growth as evaluated by monitoring the volume of
( ) ( )glioma mass A and the tissue area covered by glioma microvasculature B from day zero to day 22 after implantation of
( ) (C6 glioma cells. Animals were treated with saline or vehicle DMSO 50 mL /d IP; ns 6; open symbols or SU5416 25
)mg/kg/d, IP; ns 7; closed symbols . The volume of the glioma mass was calculated from the area covered by the glioma
( ) ( )mass analyzed planimetrically by intravital microscopy and the thickness of the glioma mass see methodology section .
The tissue area covered by the glioma microvasculature was analyzed planimetrically off-line with a computer-assisted
image analysis system. The mean"SD values are represented. Statistical analysis was performed by using ANOVA,
( )followed by unpaired Student t test. )P- .05 v control .
Figure 2. Histological examination of C6 gliomas on day 22 after glioma cell implantation into dorsal skinfold chamber
( ) (preparation of nude mice. Animals were treated with the vehicle DMSO 50 mL /d, IP; left or SU5416 25 mg /kg /d, IP;
) ( )right . H and E staining of 5 mm sections .
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(Figure 3. C6 gliomas on day 4 after glioma cell implantation and daily treatment with saline /DMSO 50 mL /d, IP, top
) ( ) (panels or SU5416 25 mg/kg/d, IP, bottom panels visualized by intravital microscopy applying transillumination right
) ( ) ( )row and combined trans- and epi-illumination techniques left row . Tumor cells are stained with Fast Blue Sigma ,
allowing exact identification of tumor mass.
( ) (Figure 4. C6 glioma microvasculature in animals treated with DMSO 50 mL /d, IP; left row or SU5416 25 mg /kg /d, IP;
) ( ) ( )right row on day 6 top panels and 18 middle and bottom panels after glioma cell implantation. Intravital multi-fluores-
cence videomicroscopy, contrast enhancement with 2% FITC-dextran IV.150
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( )and were thus grouped together control group, ns6 for
graphic representation and statistical evaluation. In the cur-
rent studies, no mortality was observed, and the sleeping
and feeding behavior of the animals was not altered during
the 22-day treatment and observation period. No significant
differences were measured comparing the body weight of
(vehicle- and drug-treated animals 30.0"2.4 g v 28.9"4.3
g on the day of glioma cell implantation; 30.0"1.4 g v
(Figure 5. Influence of Flk-1 tyrosine kinase inhibition on C6 glioma angiogenesis as evaluated by total vascular density A
) ( ) ( ) ( )and B , functional vascular density C and D , and perfusion index E and F within the peritumoral left column and
( )intratumoral right column areas from days 6 to 22 after C6 glioma cell implantation. Animals were treated with
( ) ( )saline/DMSO 50 mL /d IP; ns 6; open symbols or SU5416 25 mg /kg /d, IP; ns 7; closed symbols . Microcirculatory
parameters were analyzed off-line by using a computer-assisted image analysis system. The mean"SD values are
( )represented. Statistical analysis was performed by using ANOVA followed by unpaired Student t test. )P- .05 v control .
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28.6"4.4 g on day 6; 30.4"2.6 g v 28.0"5.2 g on day
14; and 29.9"1 g v 27.2"3.1 g on day 22 following
)glioma cell implantation .
The effect of SU5416 on early tumor growth is illustrated
in Figure 1. The tumors remained dormant in both the
control and treated groups between days zero and 6 after
tumor cell implantation. Exponential tumor growth kinetics
were observed in animals from the control group between
days 6 to 22. Daily treatment with SU5416 resulted in a
significantly lower tumor growth rate with tumor masses of
Figure 6. Influence of Flk-1 tyrosine kinase inhibition on C6 glioma microcirculation as evaluated by microvessel diameter
( ) ( ) ( )A and B , microvascular RBC velocity C and D , and blood flow of individual microvessels E and F within the peritumoral
( ) ( )left column and intratumoral right column areas for days 6 to 22 after C6 glioma cell implantation. Animals were treated
( ) ( )with saline/DMSO 50 m l / d IP; ns 6; open symbols or SU5416 25 mg /kg /d, IP; ns 7; closed symbols . Microcirculatory
parameters were analyzed off-line by using a computer-assisted image analysis system. The mean"SD values are
() )represented. Statistical analysis was performed by using ANOVA, followed by unpaired Student t test. P- .05 v control .
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up to 8% of that present in control animals by day 22 after
( )implantation Figure 1A . Inhibition of tumor growth was
clearly preceded by a marked reduction of the tissue area
covered by the newly formed glioma microvasculature in the
SU5416-treated group, indicating a reduced initial tumor
( )vascularization Figure 1B .
Figure 2 shows representative histological sections of C6
gliomas on day 22 after implantation into control or
SU5416-treated animals. Specimens from control animals
demonstrated a large tumor mass grown on the muscle and
subcutaneous tissue of the chamber preparation. In con-
trast, tumors in SU5416-treated animals were markedly
thinner. Analysis of tumors from both control and
SU5416-treated animals revealed the presence of small
anaplastic tumor cells characterized by cellular and nuclear
polymorphism. Mitotic figures were seen in both groups.
Areas of necroses, however, could not be observed in either
control or treated tumors.
To test the hypothesis that the inhibition of tumor growth
by SU5416 was due to the antiangiogenic activity of SU5416,
tumor-induced angiogenesis and tumor vascularization were
assessed by using intravital multi-fluorescence videomi-
croscopy. In the control group, implantation of C6 gliomas
into the skinfold chamber preparation induced local hyper-
emia, edema formation, and massive diapedesis of RBCs,
leading to multiple intratumoral hemorrhages within the first
( )days after tumor cell implantation Figure 3 . Initial signs of
glioma-induced angiogenesis were observed between days
2 and 4 after glioma cell implantation. The process of
angiogenesis was characterized by microvascular sprouts
and sinusoidal vessel configurations originating from dilated
and tortuously elongated host capillaries and postcapillary
venules. By day 6, these newly formed microvessels first
became branched and then subsequently interconnected to
form a complex, RBC-perfused microvascular network in
(the peritumoral area angiogenic take rate s6/6sday6
) ( )100% Figure 4 . By day 10, the area of the glioma mass
was completely vascularized. The microvasculature was
characterized by a chaotic angioarchitecture, heteroge-
neous blood perfusion, and increased permeability to
( )macromolecules as indicated by gross extravasation qq
of the high molecular weight fluorescent marker FITC-de-
xtran . The glioma microvasculature was maintained dur-150
ing tumor growth between days 10 to 22. However, the
microvascular network within the peritumoral and intratu-
moral areas revealed marked angioarchitectural differences.
High angiogenic activity and vascular density were ob-
served in peritumoral areas while the angiogenic activity
within the glioma mass was decreasing centripetally in pro-
( )portion to the distance toward the center Figure 4 . In
contrast to the control group, chamber preparations from
SU5416-treated animals did not show glioma-induced hy-
peremia, edema formation, or major intratumoral bleeding
( )see Figure 3 . Glioma-induced angiogenesis with formation
of a functional microvascular network was prevented in 5 of
( ) (7 treated animals angiogenic take rate s29% Figureday6
)4 until day 6 after glioma cell implantation. By day 10,
however, a RBC-perfused microvascular network had been
(established in all treated animals angiogenic take rateday10
)s100% . In comparison with control animals, the microvas-
culature of gliomas from SU5416-treated animals was char-
acterized by a reduced angiogenic activity, heterogeneous
vascularization, and loss of the peri-to-intratumoral vascular
( )density gradient Figure 4 between days 10 and 22. Ex-
travasation of FITC-dextran was also markedly reduced150
and solely confined to angiogenically active microvascular
( )areas q .
Figure 5 shows the quantitative analysis of total and
functional vascular densities in control and treated animals.
Throughout the entire observation period, the total vascular
density of the glioma microvasculature was significantly
reduced in tumors from SU5416-treated animals compared
with those from control animals, supporting the existence of
an inhibitory mechanism on microvascular proliferation of
(the drug based on blockage of angiogenesis Figure 5A and
)B . A greater magnitude of reduction of the total vascular
density was observed in areas with higher angiogenic activ-
(ity 60%–70% in peritumoral v 30%–40% in intratumoral
)areas, respectively . In parallel, the functional vascular den-
sity was reduced, too, indicating significant perfusion failure
and impaired vascularization in SU5416-treated tumors
( )Figure 5C and D . Again, these effects were more pro-
nounced in the well-vascularized peritumoral than in the
intratumoral areas.
Significant antiangiogenic intervention may subsequently
affect the microcirculation and microhemodynamics within
the remaining glioma microvasculature. Antiangiogenic ther-
apy leading to impaired tumor vascularization might be
compensated by several microcirculatory mechanisms in-
cluding recruitment of nonperfused microvessels, dilation of
individual microvessels, and/or increase of microvascular
[ ]RBC velocity 31 . Analysis of perfusion indices excluded a
significant recruitment of nonperfused vessels as a compen-
satory mechanism because in both the control and
SU5416-treated groups, 40% to 70% of newly formed mi-
( )crovessels were perfused with RBCs Figure 5E and F .
Similarly, no differences in microvascular diameters were
( )observed Figure 6A and B . In contrast, RBC velocity and
blood flow within remnant intratumoral microvessels were
higher in SU5416-treated tumors than in control tumors
( )Figure 6D and F . In peritumoral areas, this difference of
microvascular RBC velocity and blood flow after inhibition of
( )Flk-1/KDR activity was less pronounced Figure 6C and E .
Discussion
We have demonstrated that targeting the Flk-1/KDR tyro-
sine kinase with a small molecule inhibitor represents an
effective means to suppress tumor growth and progression
in vivo. The principal novel finding of the present study is
that the mechanism of tumor growth inhibition by the Flk-1/
KDR tyrosine kinase inhibitor SU5416 in vivo is based on a
direct inhibition of tumor-induced angiogenesis and vascu-
larization and not mediated through alternative mechanisms
independent of Flk-1-mediated microvascular proliferation.
Moreover, a detailed in vivo analysis of the tumor microcir-
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culation revealed that significant microhemodynamic
changes accompanied the antiangiogenic intervention, in-
cluding a higher RBC velocity and blood flow in individual
remnant glioma vessels when compared with controls.
The use of C6 glioma cells implanted into a transparent
dorsal skinfold chamber in athymic nude mice was based
)on several considerations, namely, 1 that C6 glioma
xenografts have been shown to represent a prototype of
[ ] )angiogenesis-dependent experimental tumors 16 ; 2 that
the subcutaneous and muscle tissue are well established
[ ]implantation sites to study C6 glioma growth 16,24,32,33
revealing growth behavior, vascularization process, and mi-
crovascular morphology similar to the intracerebral implan-
[ ] )tation site 24,32,34,35 ; and 3 that subcutaneously im-
planted C6 gliomas are among the most extensively charac-
terized experimental tumor models with respect to the func-
[ ]tional expression of VEGF and Flk-1 in vivo 16,35 . Glioma
growth, angiogenesis, and microcirculation were assessed
by means of intravital multi-fluorescence videomicroscopy.
The strength of this approach is 2-fold: First, in contrast to
alternative procedures to assess tumor vascularization such
[ ]as histological vessel counts 36 ; 3-dimensional vascular
[ ]corrosion casts 37 ; microangiography by injection of dyes
[ ] [14 ]38 ; and blood flow measurements applying C iodoan-
[ ] 133 [ ]tipyrine autoradiography 39 , Xe-washout 40 ,
[ ]laser-Doppler flowmetry 41 , and perfusion weighted mag-
[ ]netic resonance microimaging 33 , intravital multi-fluores-
cence videomicroscopy is currently the only experimental
technique that allows for a direct, continuous, and noninva-
sive visualization of the glioma microvasculature at the level
[ ]of individual microvessels 42 . Second, analyzing glioma
angiogenesis by means of intravital multi-fluorescence
videomicroscopy also allows for quantitative evaluation of
various microcirculatory parameters, which appears to be
mandatory because nutritive tissue perfusion not only de-
pends on morphological criteria such as vascular density
but also on microcirculatory and rheological parameters.
The assessment of the microhemodynamic response may
be relevant to gain more insight into mechanisms and
consequences of antiangiogenic therapy. This is especially
true when thinking about combinations of novel antiangio-
genic compounds with conventional chemotherapy, an is-
sue that has not yet been adequately appreciated in the
field of tumor angiogenesis.
[ ]In accordance with previous reports 16–18,25,43 , the
present study confirmed the fundamental role of the
VEGF-Flk-1/KDR signal transduction pathway in tumor an-
giogenesis. Recently, several molecular mechanisms regu-
lating VEFG-Flk-1/KDR expression have been proposed.
These include a genetic determination by oncogene activa-
[ ]tion and/or tumor suppressor gene inactivation 44,45 , mi-
croenvironmental stress due to intratumoral hypoxia or nutri-
[ ]tional deficiency 14,46–48 , and induction by various growth
[ ]factors and cytokines 49 . As a consequence, upon binding
of VEGF to Flk-1/KDR, the intrinsic tyrosine kinase function
is activated, which results in phosphorylation of the recep-
tor, initiation of an intracellular multistep signaling pathway,
[ ]and, finally, proliferation of the endothelial cells 50 . Poten-
tially, inhibition of any step of this cellular signaling cascade
will interfere with tumor-induced angiogenesis and tumor
[ ]growth 51 .
The selective inhibition of Flk-1/KDR activity with small
molecule tyrosine kinase inhibitors such as SU5416 repre-
sents a novel approach to antiangiogenesis therapy. One
advantage of this strategy is that using a small molecule
inhibitor allows us to bypass the need for antibody and
protein therapy. Furthermore, the lipophilic nature and low
molecular weight of SU5416 guarantee a rapid endothelial
uptake of the compound during its residence time within the
vascular compartment and thus, a rapid binding to the
[ ]intracellular domain of Flk-1/KDR 18 . Finally, SU5416 is
efficacious at doses with no measurable toxicity in the
mouse and is expected to be relatively safe compared to
conventional cytotoxic therapy because Flk-1 is downregu-
[ ]lated in angiogenically quiescent tissues 10 .
We have chosen to analyze the newly formed glioma
microvasculature separately in peritumoral and intratumoral
areas. Previous studies using in situ hybridization have
demonstrated that Flk-1 is expressed in both areas of C6
gliomas, suggesting similar mechanisms for intratumoral
[ ]and peritumoral angiogenesis in gliomas 35 . In the present
study, increased angiogenic activity and thus higher vascu-
lar density were consistently observed within peritumoral, in
comparison with intratumoral, areas. This observation is in
agreement with the hypothesis that high-grade gliomas, like
most solid tumors, grow and expand at the tumor periphery,
followed by a progressive failure in intratumoral vasculariza-
tion and microvascular perfusion. In accordance with its
inhibitory activity on endothelial cell proliferation, the most
prominent antiangiogenic activity of SU5416 was observed
within the peritumoral areas where most of the glioma-in-
duced neovascularization occurs. Consequently, this obser-
vation points to regional differences in the susceptibility of
the tumor microvasculature to the antiangiogenic interven-
tion with SU5416. Apart from this antiangiogenic effect,
inhibition of the Flk-1 tyrosine kinase with SU5416 also
reduced the angiogenesis-associated microvascular hyper-
permeability and diapedesis of RBCs.
To date, microhemodynamic changes following antian-
giogenic therapy have received only minor attention. In the
present study, we have demonstrated that suppression of
glioma growth and angiogenesis by Flk-1 tyrosine kinase
inhibition is accompanied by a higher microvascular RBC
velocity and blood flow within individual remnant tumor
microvessels than in control tumors. Based on previous
reports demonstrating that small molecule Flk-1 inhibitors
prepared in methylcellulose pellets reduce VEGF-related
microvascular hyperpermeability, and based on our obser-
vation of a reduced extravasation of the high molecular
( )marker FITC-dextran mol wts150,000 following par-150
enteral SU5416 treatment, we suggest that these microhe-
modynamic changes are due to a decreased interstitial
pressure and thus, lower microvascular resistance as a
consequence of reduced edema formation or ‘unpacking’ of
[ ]tumor vessels as recently hypothesized by Folkman 52 .
[ ]This is further strengthened by Boucher et al. 53 , who
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were able to show that intratumoral interstitial fluid pressure
is closely linked to tumor angiogenesis, thereby identifying
interstitial hypertension in solid tumors as a function of their
angiogenic activity. The authors’ observation that the inter-
stitial fluid pressure in angiogenically active solid tumors is
[ ]high in the center and decreases centrifugally 51 well
explains the reported regional differences of microhemody-
( )namic changes intratumoral v peritumoral in our study.
Nevertheless, the observed increase of RBC velocity and
blood flow in individual remnant microvessels did not suffice
to efficiently compensate for the reduced functional vascular
density due to a significant decrease of the vascular surface
(exchange area calculated from functional vascular density
)and microvascular diameters, data not shown and increase
( )of the intervascular spacing i.e., diffusion distance .
In summary, inhibition of the Flk-1 tyrosine kinase by the
small molecule inhibitor SU5416 has proven to be an effec-
tive and nontoxic strategy to control growth of angiogene-
sis-dependent tumors. For high-grade gliomas, which repre-
sent a prototype of angiogenesis-dependent tumors virtually
resistant to currently available therapies, this novel com-
pound represents a promising therapeutic alternative. The
understanding of the microcirculatory and microhemody-
namic consequences of antiangiogenic therapy in general
and of Flk-1 tyrosine kinase inhibition in particular is manda-
tory because first compounds from this class of protein
tyrosine kinase inhibitors have entered initial clinical trials.
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